CNTB · Connect Biopharma Holdings Ltd - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $169.0K | - | $1.22M | $24.12M | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $15.03M | - | $9.01M | $8.77M | $8.66M | - | - | - | - | - |
| SG&A | $4.75M | - | $6.58M | $5.12M | $3.97M | - | - | - | - | - |
| Total Operating Expenses | $19.78M | - | $15.06M | $13.47M | $12.63M | - | - | - | - | - |
| D&A | $164.0K | - | - | - | $164.0K | - | - | - | - | - |
| Operating Income | ($19.61M) | - | ($13.85M) | $13.65M | ($12.63M) | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $48.0K | - | $57.0K | $55.0K | $30.0K | - | - | - | - | - |
| Net Income | ($19.40M) | - | ($17.20M) | ($12.90M) | ($8.69M) | - | - | - | - | - |
| EPS - Basic | ($0.34) | - | ($0.23) | $0.27 | ($0.16) | - | - | - | - | - |
| EPS - Diluted | ($0.34) | - | ($0.31) | ($0.23) | ($0.16) | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $46.03M | $38.34M | $37.84M | $40.63M | $47.71M | $78.23M | $110.17M | $105.66M | $81.61M | $78.95M |
| Accounts Receivable | $0 | $13.0K | $17.0K | $0 | $8.0K | $789.0K | - | $0 | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.31M | $1.96M | $1.99M | $2.29M | $817.0K | $342.0K | - | $2.21M | - | - |
| Current Assets | $55.02M | $50.93M | $62.60M | $77.76M | $87.75M | $96.96M | $115.90M | $122.55M | $138.17M | $155.78M |
| Total Assets | $60.07M | $56.08M | $67.36M | $82.72M | $92.69M | $101.28M | $120.57M | $127.38M | $144.08M | $174.01M |
| Current Liabilities | $17.05M | $13.61M | $11.43M | $10.74M | $8.56M | $8.46M | $9.62M | $25.29M | $14.93M | $15.62M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $17.44M | $14.10M | $11.99M | $11.38M | $9.79M | $9.12M | $10.09M | $25.88M | $15.41M | $16.52M |
| Stockholders' Equity | $42.62M | $41.98M | $100.65M | $110.93M | $82.90M | $92.17M | $110.48M | $101.50M | $128.66M | $158.42M |
| Retained Earnings | ($420.23M) | ($400.83M) | ($385.73M) | ($368.53M) | ($355.63M) | ($345.36M) | ($531.70M) | ($329.73M) | ($468.76M) | ($455.91M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($16.00M) | - | - | - | ($591.0K) | - | - | - | - | - |
| Investing Cash Flow | $6.00M | - | - | - | $9.25M | - | - | - | - | - |
| Financing Cash Flow | $17.62M | - | - | - | $0 | - | - | - | - | - |
| CapEx | $0 | - | - | - | $0 | - | - | - | - | - |
| Free Cash Flow | ($16.00M) | - | - | - | ($591.0K) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -11601.8% | - | -1135.8% | 56.6% | - | - | - | - | - | - |
| EBITDA margin | -11504.7% | - | - | - | - | - | - | - | - | - |
| Net margin | -11478.1% | - | -1411.0% | -53.5% | - | - | - | - | - | - |
| Free cash flow margin | -9470.4% | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.83 | - | - | - | 0.07 | - | - | - | - | - |
| R&D / Revenue | 8893.5% | - | 739.0% | 36.4% | - | - | - | - | - | - |
| SG&A / Revenue | 2808.3% | - | 540.0% | 21.2% | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -32.3% | - | -25.5% | -15.6% | -9.4% | - | - | - | - | - |
| Return on equity | -45.5% | - | -17.1% | -11.6% | -10.5% | - | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.23 | 3.74 | 5.48 | 7.24 | 10.25 | 11.46 | 12.04 | 4.85 | 9.25 | 9.97 |
| Quick ratio | 3.23 | 3.74 | 5.48 | 7.24 | 10.25 | 11.46 | 12.04 | 4.85 | 9.25 | 9.97 |
| Cash ratio | 2.70 | 2.82 | 3.31 | 3.78 | 5.57 | 9.25 | 11.45 | 4.18 | 5.47 | 5.05 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.41 | 1.34 | 0.67 | 0.75 | 1.12 | 1.10 | 1.09 | 1.25 | 1.12 | 1.10 |
| Liabilities / Assets | 0.29 | 0.25 | 0.18 | 0.14 | 0.11 | 0.09 | 0.08 | 0.20 | 0.11 | 0.09 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.02 | 0.29 | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 0d | - | 5d | 0d | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.5x | - | 0.8x | 0.5x | 0.4x | - | - | - | - | - |
| P / S | 876.6x | - | 68.4x | 2.3x | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -55.2% | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | -123.1% | - | - | - | - | - | - | - | - | - |
| EPS growth (YoY) | -112.5% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -2608.1% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -48.6% | -54.5% | - | 0.4% | - | -9.2% | -14.1% | -35.9% | -39.6% | -41.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$64.0K totalTreatment Of Respiratory Diseases Segment$64.0K · 100.0%
Product / service
$100.0K totalClinical Trial Reports$100.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Connect Biopharma Holdings Ltd against the 5 most active filers in the same SIC group.